IgCon Therapeutics Co., Ltd.
| About us | IgCon holds a right to use yeast based human monoclonal antibody technology that is developed by our US partner. We leverage cost advantages in China to conduct animal tests and pre-clinical and clinical trials on the monoclonal antibody leads. Our company has developed our competencies on human therapeutic monoclonal antibody lead validation and development. In 2004, we successfully developed alliance relationship with a US company and an Israeli company for co-development of therapeutic antibodies for anti infectious disease and cancer. Two top candidates of human monoclonal antibody leads against CCR5 and CXCR4 for the treatment of cancer and inflammatory disease will be moved into preclinical stage in 2006. Our company has also built our competency on diagnostic product development and manufacturing. IgCon's first diagnostic product, FABP (fatty acid binding protein) cardiac infarction rapid test has received approval of SFDA in Shanghai. We launched the first diagnostic product to Chinese and Asian markets in 2005. The relevant products of second generation FABP rapid test kit are in the development pipeline. In addition, our company has developed our competencies on animal test, large scale screening, protein expression, and production of monoclonal / polyclonal antibodies for the contract service with multinational Pharma and biotech companies. We now have about 20 employees, 80% of them held college or graduate degrees. Our company's management team consists of seasoned business executives and first-class biotech scientists. The team is well acquainted with both Chinese and international markets, and has good connection with major Pharma and biotech companies, and academic research institutes worldwide. Our company aims to be one of the leading biotech company in the field of monoclonal antibody and relevant products in China and Asia. |
|---|---|
| Business Type | Manufacturer |
| Business Role | Supplier |
| Products/Services | Novel diagnostic products, specific monoclonal and polyclonal antibody |
| OEM Service | Yes |
| Our Markets | Worldwide |
| No. of Employees | 11 - 50 People |
| Estimated Annual(Sales_USD) | US$1 Million - US$2.5 Million |
| Export Percentage | 35% |
| Quality_Control | In House |
| Year Established | 2002 |
| Legal Representative(CEO) | Hua Yuda |
| Factory Location | Room 405, Block B, 563 Songtao Road, Zhangjiang Hi-Tech Park, Shanghai City. China |
